|
|
|
|
Office Locations:
|
Gustav Mahlerplein
102 Toyo lto Building, 20th Floor
Amsterdam, 1082 MA
The Netherlands
| |
|
|
|
|
|
|
Electronics & Advanced Materials
Energy & Clean Tech
Information Technology
Life Sciences & Healthcare
|
|
|
|
Founded 2009, M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. The firm's mandate is to invest in innovative technologies and products with the potential to significantly impact Merck KGaA, Darmstadt, Germany's core business areas. The fund has the mandate to invest in four focus areas: Healthcare, Life Sciences, Electronics and Frontier Tech and Sustainability. From headquarters in Amsterdam and offices in the U.S. and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. The firm takes an active role in our portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early stage investing and company creation including the creation of spin-offs to leverage Merck KGaA, Darmstadt, Germany's science and technology base. The total volume of the corporate venture fund is euro 600 million. The firm has made 90+ total investments.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
|
| Hakan Goker | |
| |
Managing Director | |
| Javier Rodriguez | |
| |
CFO | |
| Noga Yerushalmi | |
PhD | |
Investment Director | |
| Owen Lozman | |
| |
Managing Director | |
| Sebastian Schofer | |
| |
Investment Director | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
10/28/2024
|
Kivu Bioscience
|
CA
|
$92,000,000
|
Series A
|
09/18/2024
|
PictorLabs
|
CA
|
$30,000,000
|
Series B
|
08/07/2024
|
Anjuna
|
CA
|
$25,000,000
|
Series B2
|
03/27/2024
|
Celestial AI
|
CA
|
$175,000,000
|
Series C
|
03/14/2024
|
Quintessent
|
CA
|
$11,500,000
|
Seed
|
12/05/2023
|
Polaris Electro-Optics
|
CO
|
$3,000,000
|
Seed
|
|
|
|
|
|
|
|
